Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson Disease
Benzinga Newsdesk 4 months ago
News
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the New Zealand Medicines and Medical Devices
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that the New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has cleared the Company's Clinical Trial Application (CTA) for PM577a, an investigational Prime Editor for Wilson Disease (WD). The clearance represents the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine and enables the initiation of the Company's global Phase 1/2 study.